Pozen says safety data for migraine drug promising, shares up
Jan 15 (Reuters) - Medical company Pozen Inc (POZN.O) said a study evaluating its migraine drug Treximet for the risk of inducing gene toxicity had promising results, and its shares rose as much as 13 percent.
The Chapel Hill, North Carolina-based company said no genetic abnormalities were seen in peripheral blood lymphocytes
-- white blood cells -- when Treximet was given to volunteers for -- white blood cells -- when Treximet was given to volunteers for seven days.
Pozen said it has submitted findings from the study to the U.S. health regulator, Food and Drug Administration.
Pozen said the design of the safety study was approved by the FDA, which also tentatively accepted the trade name Treximet for the drug. Treximet was formerly known as Trexima.
Pozen first filed for approval of the drug in 2005, but the FDA asked the company for more data before clearing the drug. The company is still struggling to meet the FDA's requirements.
Pozen is developing Treximet with British drugmaker GlaxoSmithKline (GSK.L) (GSK.N).
Pozen shares rose to a high of $13.36, before falling back to trade up $1.36 at $13.22 in morning trade on the Nasdaq.
(Reporting by Varsha Tickoo in Bangalore; Editing by Pratish Narayanan)
((varsha.tickoo@reuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: varsha.tickoo.reuters.com@reuters.net)) Keywords: POZEN/STUDY
(C) Reuters 2008. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nBNG72415
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters